Volume 23, Number 1—January 2017
CME ACTIVITY - Research
Analysis of Anthrax Immune Globulin Intravenous with Antimicrobial Treatment in Injection Drug Users, Scotland, 2009–2010
Table 4
Initial laboratory findings of AIG-IV recipients and nonrecipients, Scotland, UK, 2009–2010*
Laboratory test [reference value] | Non-AIG-IV | AIG-IV | p value |
---|---|---|---|
Complete blood counts and differentials | |||
Leukocytes, × 109 cells/L, median (IQR) [4–11 × 109/L] | 10.9 (8.6–14.1), n = 27 | 18.9 (9.5–23.2), n = 15 | 0.02 |
Neutrophils, × 109 cells/L, median (IQR) [2–7 × 109/L] | 7.6 (5.2–10.0), n = 26 | 15.4 (7.4–19.5), n = 15 | 0.008 |
Lymphocytes, × 109 cells/L, median (IQR) [1–3 × 109/L] | 1.8 (1.3–2.5), n = 25 | 2.0 (1.3–2.7), n = 15 | 0.78 |
Hemoglobin, g/dL, mean ± SE [12–18 g/dL] | 14.0 ± 0.8, n = 27 | 14.8 ± 1.5, n = 15 | 0.61 |
Hematocrit, %, mean ± SE [35%–50%] | 41 ± 2, n = 23 | 42 ± 4, n = 13 | 0.86 |
Platelets, × 109/L, mean ± SE [150–450 × 109/L] |
214 ± 19, n = 24 |
181 ± 24, n = 15 |
0.29 |
Coagulation parameters and C-reactive protein | |||
Prothrombin time(s), median (IQR) [11–13.5 s] | 11.0 (10.0–14.0), n = 15 | 12.8 (12.0–15.0), n = 14 | 0.94 |
Partial thromboplastin time(s), median (IQR) [25–35 s] | 26.7 (24.0–36.0), n = 10 | 33.8 (30.0–39.0), n = 14 | 0.63 |
International normalized ratio, median (IQR) [0.8–1.1] | 1.1 (1.0–1.3), n = 11 | 1.1 (1.0–1.3), n = 11 | 0.36 |
C-reactive protein, nmol/L, median (IQR) [<95 nmol/L] |
21 (8–49), n = 25 |
32 (17–52), n = 14 |
0.24 |
Serum electrolytes and glucose | |||
Sodium, mmol/L, median (IQR) [135–145 mmol/L] | 137 (132–139), n = 27 | 135 (131–136), n = 15 | 0.11 |
Chloride mmol/L, median (IQR) [96–108 mmol/L] | 100 (96–101) , n = 13 | 102 (101–103), n = 14 | 0.76 |
Potassium, mmol/L, mean ± SE [3.5–5.3 mmol/L] | 4.26 ± 0.13, n = 28 | 4.35 ± 0.22, n = 13 | 0.69 |
Calcium, mmol/L, median (IQR) [2.25–2.5 mmol/L] | 2.3 (2.0–2.3), n = 28 | 2.1 (2.0–2.3), n = 12 | 0.97 |
HCO3- , mmol/L, mean ± SE [22–28 mmol/L] | 24.4 ± 1.2, n = 11 | 20.7 ± 0.9, n = 11 | 0.02 |
Glucose, mmol/L, median (IQR) [3.6–6.0 mmol/L] |
6.5 (5.6–8.1), n = 16 |
7.8 (5.3–8.9), n = 10 |
0.69 |
Renal and liver functions | |||
Blood urea nitrogen, mmol/L, median (IQR) [2.5–7.8 mmol/L] | 4.3 (3.7–6.0), n = 28 | 8.6 (7.1–13.9), n = 15 | 0.01 |
Creatinine, mmol/L, median (IQR) [40–130 μmol/L] | 75.5 (64.0–89.5), n = 28 | 102.0 (84.0–189.0), n = 15 | 0.04 |
Bilirubin, μmol/L, median (IQR) [5–17 μmol/L] | 8.0 (5.0–11.0), n = 25 | 13.5 (9.0–17.0), n = 14 | 0.02 |
Alanine aminotransferase, U/L, median (IQR) [<50 U/L] | 18.5 (14–36.5), n = 16 | 28.0 (11.0–40.0), n = 14 | 0.69 |
Alkaline phosphatase, U/L, median (IQR) [30–130 U/L] | 100 (74–189), n = 15 | 85 (56–97), n = 11 | 0.04 |
Total protein, g/L, median (IQR) [60–80 g/L] | 67 (65–75), n = 12 | 46 (41–62), n = 13 | 0.001 |
Albumin, g/L, mean ± SE [35–55 g/L] | 38.3 ± 1.1, n = 25 | 27.6 ± 2.6, n = 14 | <0.0001 |
*n values indicate no. patients for whom data were available. Bold indicates significant differences between AIG-IV recipients and nonrecipients. AIG-IV, anthrax immune globulin intravenous; IQR, interquartile range.
1These authors contributed equally to this article.